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A tumor biomarker is a molecular or process-based change that reflects the status of an un-
derlying malignancy. A tumor biomarker may be identified and measured by one or more
assays, or tests, for the biomarker. Increasingly, tumor biomarker tests are being used to
drive patient management, either by identifying patients who do not require any, or any
further, treatment, or by identifying patients whose tumors are so unlikely to respond to
a given type of treatment that it will cause more harm than good. A tumor biomarker assay
should only be used to guide management if it has analytical validity, meaning that it is
accurate, reproducible, and reliable, and if it has been shown to have clinical utility. The
latter implies that high levels of evidence are available that demonstrate that application
of the tumor biomarker test for a given use context results in better outcomes, or similar
outcomes with less cost, than if the assay were not applied. Use contexts include risk cate-
gorization, screening, differential diagnosis, prognosis, prediction of therapeutic activity or
monitoring disease course. Very few tumor biomarker tests have passed these high bars for
routine clinical application. However, if tumor biomarker tests are going to be used to drive
patient care, than an understanding, and careful assessment, of these concepts are essen-
tial, since “A Bad Tumor Biomarker Test Is as Bad as a Bad Drug.”
ª 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction over the last five to ten years, the tools to aid clinicians in theirThe term “personalized medicine” has recently gained wide-
spread acceptance among both the medical and lay commu-
nities. Fundamentally, “personalized medicine” implies
getting the right therapy to the right patient at the right
time, dose, and schedule. Of course since the beginning of
medicine, physicians have tried to determine the correct diag-
nosis and match appropriate therapy to the patient at hand
with the best evidence available (Schilsky, 2009). However,1.
4
ochemical Societies. Publquest to personalize medicine have become increasingly
sophisticated, and perhaps no more so than in the field of
oncology. The revolution in molecular biology over the last
three decades has provided a much better understanding of
the aberrant pathways that drive the malignant process. The
pharmaceutical industry has exploited this better under-
standing of tumor biology to develop therapeutic agents that
are targeted to these aberrant pathways. Finally, immunologic
and molecular genetic technologies that were unthinkable asished by Elsevier B.V. All rights reserved.
Table 1 e Intended use contexts for tumor biomarker tests.
 Risk categorization
 Screening for new cancer
 Differential diagnosis
B Cancer vs. benign
B Epithelial vs. hematopoietic vs. mesenchymal
B Organ of origin
 Prognosis
B Early stage
B Metastatic
 Prediction of therapy activity
B Early stage
B Metastatic
 Monitoring disease status
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diagnostic approaches that illuminate the specific changes
in cancer versus normal cells.
In spite of these advances, there seems to be more hype
than reality. Very few molecular diagnostic tests have gained
recommendation by major guidelines bodies, and only a few
tumor biomarker tests have proven successful in the market-
place (Hayes et al., 2013). Further, some tumor biomarker
assays are commercially available without documented evi-
dence that they improve patient care, and yet are being
ordered and used by many clinicians. What has led to this
relative state of chaos? The remainder of this review will be
dedicated to the theme that “A Bad Tumor Marker Test Is as
Bad as a Bad Drug (Hayes et al., 2013),” detailing the current
state of affairs and knowledge about what is needed to take
a tumor biomarker test from a good idea to clinical reality.B Early stage
B Metastatic2. What is a tumor biomarker test?
It is important to understand the distinction between a tumor
biomarker and a test for it (Institute of Medicine, 2012). A tu-
mor biomarker is an indication that a normal tissue is likely
to or has become malignant, and/or it provides an indication
of how a malignancy will behave, either naturally or in the
context of therapy. A tumor biomarker might be a molecular
change, such as in a nucleic acid, protein, or metabolite. It
might also be a process change, such as an alteration in tissue
appearance. Further, the presence of a benign process within
malignant tissuemight also be considered a tumor biomarker,
such as neovascularization, that in itself is not malignant but
may provide an indication of the expected biology of the can-
cer. Tumor biomarkers may be detected and/or monitored in
tissue, blood, or relevant secretions, such as urine, stool,
sputum, or breast nipple aspirates.
A tumor biomarker test is used to identify or measure the
perturbations reflected by the tumor biomarker. There may
be one or more assays or tests that provide some indication
of the status of the tumor biomarker. These may measure
the same thing, or they may measure very different perturba-
tions in the biomarker. The erbB2 gene, which encodes for the
HER2 protein, provides a good example of this issue. There are
at least 3 commercially available assays for in situ hybridiza-
tion to determine amplification of the gene, several assays,
mostly based on immunohistochemistry, that quantify rela-
tive expression of the HER2 protein in cancer tissue, and
others that quantify relative expression of the HER2 message
(Wolff et al., 2013a,b). Recently, mutations in erbB2 that acti-
vate the protein without over-expression have been reported.
Each of these may a give related indication of HER2 activity,
but they are all very different andmay ormay not provide use-
ful similar clinical information.3. How is a tumor biomarker test used in the clinic?
Todevelopandvalidate a tumorbiomarker test, several critical
issuesmust be addressed. First, and foremost, onemust estab-
lish the intended use or context (Table 1). These include risk
categorization, screening, diagnosis, prognosis, prediction oftherapeutic response, and monitoring (Henry and Hayes,
2006). A tumor biomarker test might be used to place an unaf-
fected individual into one or more categories of risk, in which
he/she might take preventive or screening strategies that
would otherwise be unacceptable. Perhaps the best examples
of this use is the presence or absence of a germline Y chromo-
some. Men do not generally undergo screening or prevention
for breast cancer, while women do not need to be concerned
about their risk of prostate cancer. A second use context is
screening for the presence of a new cancer. Few if any tumor
biomarker tests have been successfully developed for this
role, althoughasanexample, useofhumanpapillomavirusas-
says have been incorporated into standard of care for
screening for cervical cancers. Diagnosis, or more accurately
differential diagnosis, is an important issue in pathology. Tu-
mor biomarker tests, principally immunologically-based, are
usedonoccasion todistinguishbenign frommalignant tissues,
and more frequently to determine that an undifferentiated
cancer is epithelial versus hematopoietic or mesenchymal.
The most commonly used tumor biomarker assays are
used to predict the future behavior of an established cancer.
The term “prognostic factor” refers to a tumor biomarker
test that infers a high or low risk of a cancer-related event
assuming the patient receives no more therapy than he/she
has already received, if any. The most widely accepted prog-
nostic factors in cancer are the size of the primary tumor,
the presence or absence of regional lymph nodes or distant
metastases. These have been codified into the now classic
“TNM” staging system maintained by the Joint Commission
on Cancer (AJCC, 2010).
In contrast, predictive factors, also designated response
modifier elements, are used to estimate the relative likelihood
that a cancer will respond to a class of, or even individual,
therapeutic agents. Perhaps the oldest and most widely used
example of a predictive tumor biomarker is the estrogen re-
ceptor (ER), which may be measured in many ways using
different assays. Regardless, patients with ER negative breast
cancers do not benefit from endocrine (anti-estrogen) therapy,
Table 2 e Important definitions for tumor biomarker semantics.
Analytical validity
 Does the tumor biomarker test accurately and reliably
measure the analyte of interest in the appropriate
patient specimen?
Clinical validity
 Does the tumor biomarker test accurately and reliably
identify a clinically or biologically defined disorder, or
separate one population into two or more groups with
distinct clinical or biological outcomes or differences?
Clinical utility
 Are there high levels of evidence that use of the tumor
biomarker test to guide clinical decisions result in
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 9 6 0e9 6 6962while nearly one-half of those with ER positive breast cancers
do (Hammond et al., 2010a,b).
Finally, serial tumor biomarker tests may be used to
monitor the course of therapy, or even follow-up, to deter-
mine if a patient should remain on a given management
plan or, perhaps, should have his/her strategy altered due to
apparent progression. For example, there are assays for
several circulating proteins, such as carcinoembyonic anti-
gen, CA19-9, CA125, prostate specific antigen, and MUC-1 pro-
tein, that are commonly used to monitor patients with
colorectal, pancreatic, ovarian, prostate, and breast cancers,
respectively.improved measurable clinical outcomes compared with
those if the biomarker test results were not applied?
Modified from (Teutsch et al., 2009).
4. When should a tumor marker test be used to guide
clinical care?
Although not absolutely, in general application of a new ther-
apeutic strategy, especially a new drug, requires the presence
of high levels of evidence that the drug is safe and effective.
Consensus definitions of these two terms are reasonably
accepted in the field, although one might argue over the de-
gree of toxicities that are a patient will tolerate or the exact
clinical endpoint that is considered “meaningful.” The regula-
tory framework in most developed countries for therapeutics
is consistent and well-understood by all involved. For
example, introduction of a new anti-cancer drug into the clin-
ical arena usually requires evidence from prospective ran-
domized clinical trials that at least event-free, if not overall,
survival is improved with statistical significance at a reason-
ably low cost of toxicity.
In contrast, the regulatory environment for review and
commercial use of tumor biomarker tests is much less clear
(Hayes et al., 2013). Clearance or approval of a tumor
biomarker test by the Food and Drug Administration (FDA)
does not necessarily mean that it improves patient outcomesFigure 1 e The vicious cycle of tumor biomarker reseor should be used. Further, because of FDA enforcement
discretion, laboratory developed tests (LDTs) can be generated
and used to direct clinical care without FDA approval, as long
as they are performed within a laboratory that follows good
laboratory practices according to the Clinical Laboratory
Improvement Amendments (CLIA) Act of 1988. Use of a tumor
biomarker to guide treatment decisions within a clinical trial
has always required application of an investigational device
exemption (IDE) to the FDA. Recently, the FDA has announced
that it will carefully review the enforcement discretion deci-
sion regarding use of an LDT to care for patients in routine
care, but it is expected that discussion about this decision
will evolve over the next several years.
Taken together, these circumstances have led to a “vicious
cycle” in which tumor marker tests are generally felt to have
less value than therapeutics for cancer management
(Figure 1) (Hayes et al., 2013). As a result, clinical decisions to
use a tumor biomarker test, recommendation by guidelinesarch. From (Hayes et al., 2013) with permission.
Table 3 e Elements of tumor marker studies that constitute levels of evidence determination.a
Category A B C D
Trial design Prospective Prospective using
archived samples
Prospective/
observational
Retrospective/
observational
Clinical trial PRCT designed to address
tumor marker
Prospective trial not
designed to address tumor
marker, but design
accommodates tumor
marker utility.
Prospective observational
registry, treatment and
follow up not dictated
No prospective aspect to
study
Accommodation of
predictive marker
requires PRCT
Patients and patient data Prospectively enrolled,
treated, and followed in
PRCT
Prospectively enrolled,
treated, and followed in
clinical trial and,
especially if a predictive
utility is considered, a
PRCT addressing the
treatment of interest
Prospectively enrolled in
registry, but treatment
and follow up standard of
care
No prospective stipulation
of treatment or follow up;
patient data collected by
retrospective chart review
Specimen collection,
processing, and
archival
Specimens collected,
processed and assayed for
specific marker in real
time
Specimens collected,
processed, and archived
prospectively using
generic SOPs. Assayed
after trial completion
Specimens collected,
processed, and archived
prospectively using
generic SOPs. Assayed
after trial completion
Specimens collected,
processed and archived
with no prospective SOPs
Statistical Design and
analysis
Study powered to address
tumor marker question
Study powered to address
therapeutic question;
underpowered to address
tumor marker question
Study not prospectively
powered at all.
Retrospective study
design confounded by
selection of specimens for
study
Study not prospectively
powered at all.
Retrospective study
design confounded by
selection of specimens for
study
Focused analysis plan for
marker question
developed prior to doing
assays
Focused analysis plan for
marker question
developed prior to doing
assays
No focused analysis plan
for marker question
developed prior to doing
assays
Validation Result unlikely to be play
of chance
Result more likely to be
play of chance that A, but
less likely than C
Result very likely to be
play of chance
Result very likely to be
play of chance
Although preferred,
validation not required
Requires one or more
validation studies
Requires subsequent
validation studies
Requires subsequent
validation
From (Simon et al., 2009) with permission.
a PCRT ¼ prospective randomized controlled trial; SOPs ¼ standard operating practices.
Table 4 e Revised determination of levels of evidence using
elements of tumor marker studies.a
Level of
evidence
Category
from Table 1
Validation studies
available
I A None required
I B One or more with consistent results
II B None or inconsistent results
II C 2 or more with consistent results
III C None or 1 with consistent results
or inconsistent results
IVeV D NA
From (Simon et al., 2009) with permission.
a NA ¼ Not applicable, since LOE IV and V studies will never be
satisfactory for determination of medical utility.
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sions from third party payers for their use, have been rela-
tively arbitrary, with insufficient data to support or refute
the relative value of the tests. If indeed clinicians are to truly
provide personalized oncology, this vicious cycle needs to be
broken. Therefore, over the last two decades, several experts
have attempted to develop structured recommendations for
criteria that might be used in a manner analogous to those
applied to decisions regarding new therapeutics.
Teutsch et al., representing the Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) Initiative of
the United States Centers for Disease Control, suggested three
important semantic definitions for tumor biomarker research:
Analytical validity, clinical validity, and clinical utility
(Table 2) (Teutsch et al., 2009). Analytical validity implies that
the test for the tumor biomarker is accurate and reliable in
the type of specimen towhich it will be applied. Clinical validity
refers to evidence that the tumor biomarker test divides a sin-
gle population into two or more distinct groups, based on
biology or clinical outcomes, with statistical significance. Incontrast, clinical utility requires that high levels of evidence
demonstrate that use of the tumor biomarker test improves
clinical outcomes or that clinical outcomes are identical
with less cost or toxicity.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 9 6 0e9 6 6964Efforts to organize tumor biomarker test results into these
categories, and to grade the levels of evidence that would
help determine if a marker has clinical utility, have been pro-
posed (Hayes et al., 1996; Simon et al., 2009). The ideal level of
evidence should come from a prospective trial in which the
tumor biomarker clinical utility for a specific use is the main
objective. Indeed, several trial designs have been proposed to
accomplishsucha task (Freidlinetal., 2010;Sargentetal., 2005).
Prospective trials are time consuming and costly. There-
fore, there are precious few examples of prospective trials in
which the primary objective is to determine clinical utility ofFigure 2 e A roadmap for tumor biomarker test development (adapted from
permission. LDT [ laboratory developed test. See.a specific tumor biomarker test. However, one obvious differ-
ence between therapeutics and diagnostics is that the latter
can be assessed using archived specimens that have been
collected and stored for future use. In this regard, Simon,
Paik and Hayes suggested that high levels of evidence can be
ascertained by performing “prospective retrospective” ana-
lyses of a tumor biomarker test using archived specimens
(Simon et al., 2009). However, these criteria are quite rigorous,
necessitating use of specimens collected from patients who
participated in prospective trials that addressed the specific
use intended for the tumor biomarker test. They ranked theOmics e based test development (Institute of Medicine, 2012)) with
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cific tumor biomarker test has clinical utility for a specific clin-
ical use (Simon et al., 2009). Table 3 shows this hierarchy with
the requirements that must be met to fit each category, while
Table 4 provides the required elements to reach level 1 evi-
dence for clinical utility.
In 2012, a committee convened by the Institute of Medicine
(IOM) distilled these concepts into a roadmap to guide investi-
gators from a good idea to generating clinical utility for a
tumor biomarker (Figure 2) (Institute of Medicine, 2012). The
process outlined in Figure 2 represents a process from new
biomarker discovery to development of a “locked down” test
for that biomarker that has high analytical validity and has
some evidence of clinical validity, as defined by EGAPP. Prefer-
ably, but not absolutely, at least in the United States, this step
should be performed within a CLIA-approved laboratory,
which ensures that good laboratory practices are followed.
When the investigator is satisfied that the tumor biomarker
test has sufficiently high analytical and clinical validity, it
should be taken across the “bright line” to determine if it
has clinical utility for a given use context using one of the stra-
tegies discussed in the preceding paragraph. If a prospective
clinical trial is pursued to test for clinical utility, the FDA
should be consulted to determine if an IDE is, or is not,
required (See IOM report (Institute of Medicine, 2012)).5. How should the results of tumor biomarker test
investigations be reported?
A critical component of determining the relative level of evi-
dencetosupportanalyticalvalidityandclinicalutilityofa tumor
biomarker test is the quality of the reporting of the studies that
areused toevaluate themarkerassay. Several effortshavebeen
proposed to standardize reporting of tumor biomarker test
studies, analogous to those required for therapeutic investiga-
tions (McShane and Hayes, 2012; Moher et al., 2001). These
have included suggested descriptions of the pre-analytical fac-
tors that could substantially influence reproducibility of the
assay; the so-called Biospecimen reporting for improved study
quality (BRISQ) criteria (Moore et al., 2012). Furthermore, the
Reporting Recommendations for Tumor Marker Prognostic
Studies (REMARK), which have been recently updated, are
now required by amany oncology journals formanuscript sub-
missions describing tumor biomarker results (Altman et al.,
2012). In an effort to bring evenmore transparency to the field,
a registry for prospective or prospective retrospective tumor
biomarker studies has been established, so that investigators
can document that their studies were truly prospectively
planned (Andre et al., 2011). It is hoped that eventual participa-
tion in this or similar registries will decrease the now-rampant
problem of publication bias for tumor biomarker studies,
much in theway that the required registration in clinicaltrials.-
gov has done for therapeutic trials (McShane and Hayes, 2012).6. Summary
As we enter the era of truly personalized medicine in
oncology, it is critical that we continue to apply the scientificmethod to the consideration of what tumor biomarker tests
to use to guide patient management. Maintaining this level
of rigor may become even more difficult, yet will remain
even more important, as the fields of genomic-based thera-
pies continue to evolve. Applying diagnostic or therapeutic
strategies because they make sense, or because they are
appealing, is a seductive but dangerous approach. It is essen-
tial that any tumor biomarker test used to guide treatment
management have both analytical validity and clinical util-
ity. As we move into this brave new world, we must keep
in mind that “A Bad Tumor Biomarker Test Is as Bad as a
Bad Drug.”R E F E R E N C E S
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